Liu L, Su X, Quinn WJ, Hui S, Krukenberg K, Frederick DW, et al
Even though both belong to the same family of medications called GLP-1 receptor agonists, Wegovy seems to have a more pronounced effect on weight loss
Retatrutide (development code LY3437943) is a synthetic peptide developed by Eli Lilly that acts as an agonist at three distinct receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
The FDA has never approved this combination, and clinical literature documenting its safety is essentially nonexistent
Because it works this way on different metabolic pathways, retatrutide is becoming a strong option in new weight loss medicines
Being involved in over 300 enzymatic reactions, magnesium is crucial for proper nerve function and neurotransmitter regulation